Vir Biotechnology

VIR · Nasdaq · United States

Share price · VIR

$9.15-0.34 (-3.58%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VIR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Nov 2026-17.8%
  2. 9 Nov 2026+11.8%
  3. 6 Nov 2026+10.8%
  4. 30 Sep 2026+5.0%

    Nothing announced by VIR that day or the session before.

  5. 1 Sep 2026+6.3%

    Nothing announced by VIR that day or the session before.

  6. 25 Aug 2026+8.1%

    Nothing announced by VIR that day or the session before.

  7. 21 Aug 2026+6.2%

    Nothing announced by VIR that day or the session before.

  8. 6 Aug 2026-3.8%
  9. 24 Jul 2026-7.0%
  10. 1 Jul 2026-6.2%

    Nothing announced by VIR that day or the session before.

Share of unusual movement by asset

For each asset, the share of VIR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
HBsAgMonoclonal antibody
Hepatitis Delta
Chronic Hepatitis Delta

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Tobevibart (VIR-3434)Phase 3Viral Hepatitis
Est. primary completion 2026-12 · NCT07128550 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Tobevibart (VIR-3434)Phase 2Viral Hepatitis
Est. primary completion 2029-03 · NCT07142811 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Tobevibart (VIR-3434)Phase 2Hepatitis D, Chronic
Est. primary completion 2031-11 · NCT05461170 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 November 2026Topline resultTobevibart (VIR-3434)ECLIPSE 1 Phase 3 meets its primary endpoint
Vir Biotechnology · Source ↗
8 November 2026Topline resultElebsiranECLIPSE 1 Phase 3 meets its primary endpoint
Vir Biotechnology · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3-$0.2M$80M$228M+ $236M short-term inv.$96M-$106M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$239M$135M$288M+ $250M short-term inv.—$123M operating cash flowreport ↗
2026-Q1-<$0.1M$109M$283M+ $196M short-term inv.$126M-$132M operating cash flowreport ↗
2025-Q3$0.2M$151M$179M+ $328M short-term inv.$163M-$168M operating cash flowreport ↗
2025-Q2$1.2M$98M$306M+ $388M short-term inv.$111M-$120M operating cash flowreport ↗
2025-Q1$3.0M$119M$368M+ $517M short-term inv.$121M-$78M operating cash flowreport ↗
2024-Q3$2.4M$195M$264M+ $741M short-term inv.$214M-$171M operating cash flowreport ↗
2024-Q2$3.1M$105M$317M+ $850M short-term inv.$138M-$78M operating cash flowreport ↗
2024-Q1$56M$100M$180M+ $985M short-term inv.$65M-$109M operating cash flowreport ↗
2023-Q3$2.6M$148M$472M+ $1.2B short-term inv.$163M-$156M operating cash flowreport ↗
2023-Q2$3.8M$172M$687M+ $1.2B short-term inv.$195M-$389M operating cash flowreport ↗
2023-Q1$63M$158M$843M+ $1.4B short-term inv.$141M-$126M operating cash flowreport ↗
2022-Q3$375M$114M$984M+ $1.4B short-term inv.—$118M operating cash flowreport ↗
2022-Q2-$41M$115M$1.5B+ $654M short-term inv.$76M$960M operating cash flowreport ↗
2022-Q1$1.2B$90M$836M+ $400M short-term inv.—$550M operating cash flowreport ↗
2021-Q3$104M$99M$728M+ $56M short-term inv.—-$106M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$69M$456M$241M+ $229M short-term inv.$110M-$392M operating cash flowreport ↗

For fiscal year 2025, Vir Biotechnology reported revenue of $68.56M, down 7.6% YoY. R&D spend was $455.97M, down 10.0% YoY, and the company held $241.07M in cash and equivalents. The net loss for the period was $437.99M.

Vir announced a global strategic collaboration with Astellas to co-develop and co-commercialize VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager targeting PSMA for prostate cancer. Vir will receive $335M in upfront and near-term payments, including $240M in cash, a $75M equity investment at a 50% premium, and a $20M near-term milestone, with eligibility for up to $1.37B in development, regulatory, and sales milestones plus tiered double-digit royalties on ex-U.S. net sales. Development costs will be shared 60% Astellas / 40% Vir, with Astellas leading U.S. commercialization while Vir retains a co-promote option, and Astellas holding exclusive ex-U.S. commercialization rights; updated VIR-5500 Phase 1 data are to be presented at the 2026 ASCO Genitourinary Cancers Symposium.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$74M$507M$319M+ $678M short-term inv.$130M-$446M operating cash flowreport ↗
2023-FY$86M$590M$261M+ $1.3B short-term inv.$154M-$779M operating cash flowreport ↗
2022-FY$1.6B$475M$868M+ $1.5B short-term inv.—$1.7B operating cash flowreport ↗
2021-FY$1.1B$448M$363M+ $217M short-term inv.—-$48M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 33 sales ($8.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-15Sabatini Brent · SVP, Chief Accounting OfficerAward / grant50,000——Form 4
2026-11-15Sawaf Aziz · EVP, Chief Financial OfficerAward / grant75,000——Form 4
2026-11-15Sawaf Aziz · EVP, Chief Financial OfficerAward / grant (derivative)150,000——Form 4
2026-11-03de Verneuil Vanina · EVP, General Counsel, Corp SecOpen-market sale2,407$11.10$27KForm 4
2026-11-02de Verneuil Vanina · EVP, General Counsel, Corp SecOpen-market sale1,343$11.33$15KForm 4
2026-10-27Topalian Suzanne Louise · directorAward / grant8,000——Form 4
2026-10-27Topalian Suzanne Louise · directorAward / grant4,731——Form 4
2026-10-27Topalian Suzanne Louise · directorAward / grant (derivative)16,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 251 reporting institutions held 140.1M shares ($1.2B, 81.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.17,998,329$161.3M
2ARCH Venture Management, LLC12,916,663$115.7M
3SB INVESTMENT ADVISERS (UK) LTD10,948,093$98.1M
4VANGUARD PORTFOLIO MANAGEMENT LLC9,215,577$82.6M
5GSK plc8,550,954$76.6M
6STATE STREET CORP7,141,094$64.0M
7VANGUARD CAPITAL MANAGEMENT LLC5,382,103$48.2M
8GOLDMAN SACHS GROUP INC3,250,227$29.1M
9MORGAN STANLEY2,854,205$25.6M
10ADAR1 Capital Management, LLC2,744,714$24.6M
11GEODE CAPITAL MANAGEMENT, LLC2,657,843$23.8M
12DIMENSIONAL FUND ADVISORS LP2,579,678$23.1M
13CITADEL ADVISORS LLC2,098,476$18.8M
14FMR LLC2,071,848$18.6M
15Soleus Capital Management, L.P.2,002,000$17.9M